Seer (SEER) Receivables - Accured (2021 - 2022)
Seer (SEER) posted quarterly Receivables - Accured of $900000.0 for Q3 2022, up 50.0% quarter-over-quarter from $600000.0 in Q2 2022.
Powered by 
Analysis
Seer (SEER) Receivables - Accured (2021 - 2022) Analysis & Trends
Seer's Receivables - Accured history runs 2 years deep, the most recent figure standing at $900000.0 for Q3 2022.
- In Q3 2022, Receivables - Accured changed N/A year-over-year to $900000.0; the TTM figure through Sep 2022 stood at $900000.0 (changed N/A YoY), while the FY2021 annual figure was $300000.0, changed N/A from the prior year.
- Receivables - Accured for Q3 2022 stood at $900000.0, up from $600000.0 in the prior quarter.
- The five-year high for Receivables - Accured was $900000.0 in Q3 2022, with the low at $300000.0 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Seer | 107.57 Mn | 107.57 Mn | 1.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | 900,000.00 |
| Jun 30, 2022 | 600,000.00 |
| Mar 31, 2022 | 500,000.00 |
| Dec 31, 2021 | 300,000.00 |